Introduction In a surprising turn of events, Swiss pharmaceutical giant Novartis has decided to step back from the pursuit of much-anticipated acquisition of Cytokinetics, a US based cardiovascular drug developer. This sudden decision has sent ripples through the market, prompting a significant drop in Cytokinetics’ stock value and leaving investors and industry analysts questioning the